CLINICS 2010;65(12):1247-1251 22. Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy- General (FACT-G). Eval Health Prof. 2005;28:192–211, doi: 10.1177/ 0163278705275341. 23. Rodriguez-Roisin R, Anzueto A, Bourbeau J, Calverley P, DeGuia T, Fukuchi Y, et al. GOLD – Global Initiative for Chronic Obstructive Pulmonary Disease – Pocket Guide to COPD Diagnoses, Management and Prevention. A Guide for Healthcare Professionals. Medical Communications Resources, Inc.; 2009. 24. Saitoh E, Yokomizo Y, Chang C-H, Eremenco S, Kaneko H, Kobayashi K. Cross-cultural validation of the Japanese version of the lung cancer subscale on the Functional Assessment of Cancer Therapy-Lung. J Nippon Med Sch. 2007;74:402–8, doi: 10.1272/jnms.74.402. 25. Yoo H, Suh C, Kim S, Eremenco S, Kim H, Kim S. Korean translation and validation of the Functional Assessment of Cancer Therapy-Lung (FACT-L) version 4. Qual Life Res. 2006;15:161–6, doi: 10.1007/s11136- 005-8752-x. 26. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the Functional Assessment of Cancer Therapy-Taxane (FACT-taxane). Cancer. 2003;98:822–31, doi: 10.1002/cncr.11578. 27. Dapueto JJ, Francolino C, Servente L, Chang CH, Gotta I, Levin R, et al. Evaluation of the Functional Assessment of Cancer Therapy-General (FACT-G) Spanish version 4 in South America: classic psychometric and item response theory analyses. Health Qual Life Outcomes. 2003;1:32, doi: 10.1186/1477-7525-1-32. 28. Eton DT, Cella D, Yount SE, Davis KM. Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12). Lung Cancer. 2007;57:339–47, doi: 10.1016/j.lungcan.2007.03.021. 29. Hammerschmidt S, Wirtz H. Lung cancer: current diagnosis and treatment. Dtsch Arztebl Int. 2009;106:809–18; quiz 819–20. 30. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, et al. Lung cancer susceptibility model based on age, family history and genetic variants. PLoS One. 2009;4:e5302, doi: 10.1371/journal.pone.0005302. 31. Ozturk A, Sarihan S, Ercan I, Karadag M. Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy. Am J Clin Oncol. 2009;32:65–72, doi: 10.1097/COC.0b013e31817e6ec2. 32. Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht ML, et al. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest. 2004;125:439–45, doi: 10.1378/chest.125.2.439. 1251